NCT05289245
Recruiting
Not Applicable
A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Cystic Fibrosis (CF-CHINA)
ConditionsPulmonary Function
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pulmonary Function
- Sponsor
- Peking Union Medical College Hospital
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Change in spirometry (FEV1 and FVC) of lymphangioleiomyomatosis patients.
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
Cystic fibrosis (CF) is a rare autosomal recessive disease involving multiple organs, especially the lungs and digestive organs. It is most commonly seen in Caucasians. Only a few Chinese CF patients have been described in literature, taking into account the large population of China. The main objectives of this study are to accurately evaluate the prevalence of CF, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Fulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with no respiratory infections for nearly 4 weeks; Subjects (or their guardians) signed informed consent.
Exclusion Criteria
- •Patients with other bronchiectasis who did not meet the inclusion criteria; Those with severe cardiac or renal disease
Outcomes
Primary Outcomes
Change in spirometry (FEV1 and FVC) of lymphangioleiomyomatosis patients.
Time Frame: 10 years
Spirometry will be evaluated at baseline and through study completion, an average of 3 years.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Clinical and Genetic Profile of Pediatric Patients With Cystic Fibrosis in Sohag.Cystic FibrosisNCT05599958Sohag University152
Completed
Phase 2
Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis PatientsCystic FibrosisNCT00499837Kamada, Ltd.21
Unknown
Not Applicable
Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF).Cystic FibrosisAdherence, MedicationNCT04215796Dosentrx Ltd.10
Completed
Not Applicable
Biomarkers of Injury and Destruction in the Cystic Fibrosis LungCystic FibrosisNCT01805713University of Minnesota150
Completed
Not Applicable
Benefits and Risks of Newborn Screening for Cystic FibrosisCystic FibrosisLung DiseasePseudomonas InfectionsNCT00014950National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)